Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 4/20 | 0.68 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.68 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.68 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.68 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.68 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.68 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17086763 | 0.82 | GRM7 (0.54) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL13448757 | 0.82 | GRM7 (0.54) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL13448758 | 0.82 | GRM7 (0.54) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL28760640 | 0.82 | HDAC3 (0.50) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL1162342 | 0.81 | CNR1 (0.49) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL2841871 | 0.81 | HDAC4 (1.00) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL3727820 | 0.80 | HDAC3 (0.48) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL16828334 | 0.80 | HDAC3 (0.49) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL1978851 | 0.79 | HDAC4 (0.68) | HDAC4HDAC7HDAC5HDAC3HDAC1 | |
| SCHEMBL13448625 | 0.79 | FFAR2 (0.69) | HDAC4HDAC7HDAC5HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1640359-A2 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMACEUTICALS, INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1042275-B1 | ANTICONVULSANT AND CENTRAL NERVOUS SYSTEM-ACTIVE BIS(FLUOROPHENYL)ALKYLAMIDES | NPS PHARMA INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030199589-A1 | Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses | NPS PHARMACEUTICALS, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| US-6617358-B1 | Also bis(optionally chloro- or fluoro-substitutedphenyl)alkylcarboxy acids and esters | NPS PHARMACEUTICALS, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | HDAC4 1864/4885HDAC7 1982/4885HDAC5 2357/4885 |
| US-20030199589-A1 | Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses | GABRE, GABRA2, GABRB2 | HDAC4 280/4885HDAC7 585/4885HDAC5 168/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HDAC4 755/4885HDAC7 941/4885HDAC5 1526/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | HDAC4 755/4885HDAC7 941/4885HDAC5 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.